{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-015074","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.570260+00:00","generated_at":"2026-06-02T21:35:02.830970+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OPKO Health to sell BioReference assets to Labcorp for $237.5M; Q1 net loss $81.8M","bullets":["Agreed to sell select BioReference Health assets to Labcorp for $237.5M; assets generate ~$100M annual revenue; closing expected H2 2024.","Q1 total revenue $173.7M (down 27% YoY); net loss $81.8M ($0.12/share) vs $18.3M loss a year ago.","Issued $230M 3.75% convertible notes due 2029; exchanged $144.4M of existing 4.50% notes; used $50M to repurchase common stock.","FDA cleared IND for MDX2001 tetraspecific antibody for solid tumors; Phase 1 trial enrollment expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-015074","json":"https://secwatch.observer/filing/0001437749-24-015074.json","markdown":"https://secwatch.observer/filing/0001437749-24-015074.md","text":"https://secwatch.observer/filing/0001437749-24-015074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000143774924015074/0001437749-24-015074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000143774924015074/opk20240503_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:35:02.830970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7396bb910e58437418ac9f351c8f9fd2ca429bb2","claim":"OPKO HEALTH, INC. reported three months ended March 31, 2024 results: revenue $173.7 million, net income $81.8 million, or $0.12 per share, EPS $0.12 per share.","evidence_excerpt":"was $34.4 million in the first quarter of 2024 compared with $40.0 million in the 2023 period. ● Consolidated: Consolidated total revenues for the first quarter of 2024 were $173.7 million compared with $237.6 million for the comparable period of 2023. Operating loss for the first quarter of 2024 increased to $71.5 million from $30.6 million for the 2023 quarter,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/944809/000143774924015074/0001437749-24-015074-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"$173.7 million"},{"label":"Net income","value":"$81.8 million, or $0.12 per share"},{"label":"EPS","value":"$0.12 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}